Since the first successful kidney transplant in 1954, transplant medicine has advanced significantly, achieving favorable one-year outcomes. However, despite excellent short-term outcomes, long-term renal allograft survival remains sub-optimal, with acute rejection continuing to be a major contributor to death-censored...
Elizabeth Cho, Yvette Y. Lopez, S. Alasfar· Journal of Clinical Medicine· 0 citations
Daratumumab may serve as an adjunctive option for refractory AMR with persistent DSAs by targeting plasma cell-mediated alloantibody production by targeting CD38-expressing cells.
S. Sridhara, Elizabeth Cho, J. Nelson et al.· Transplantation Proceedings· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.